No Data
No Data
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
The concept of contract research organizations is on the rise. Wuxi AppTec (02359) rose by 4.97%. Institutions predict that the performance of the pharmaceutical sector will show a marginal improvement trend.
Jingu Finance News | The concept of contract research organizations is up across the board. As of press time, Genscript Bio (01548) rose 6.07%, Wuxi AppTec (02359) rose 4.97%, Viva Biotech (01873) rose 4%, and Pharmaron (03759) rose 3.64%. On the news front, Xingye Securities issued a research report stating that the market attention to the pharmaceutical sector has gradually recovered recently. Looking back, the pharmaceutical sector experienced a downtrend of more than 2 months, with the CSI 300 Index down 11.0% (as of the close of August 2), while the Shanghai and Shenzhen 300 Index was also down 6.1% during the same period. Currently, the pharmaceutical sector is valued
Haitong Int'l: active investment and financing market, CRO companies accelerate layout of AI+pharmaceutical application technology.
With the continuous advancement of AI technology and the enhanced professional capabilities of CRO companies, it is expected that there will be more innovative breakthroughs in the field of drug research and development in the future.
Hong Kong stock concept tracking | Diabetes prevention and control action plan released, significant progress has been made in the innovative drug research and development of these enterprises (with concept stocks).
According to Frost & Sullivan data, the scale of China's diabetes medication market is expected to reach 167.5 billion yuan by 2030.
No Data